Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU

[1]  W. Seeger,et al.  Updated treatment algorithm of pulmonary arterial hypertension. , 2013, Journal of the American College of Cardiology.

[2]  D. Badesch,et al.  [Definitions and diagnosis of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[3]  F. Scaglione,et al.  The impact of drug-drug interactions on pulmonary arterial hypertension therapy. , 2014, Pulmonary pharmacology & therapeutics.

[4]  H. Ghofrani,et al.  Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. , 2014, Pulmonary pharmacology & therapeutics.

[5]  L. Rubin,et al.  Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension , 2014, Expert opinion on drug safety.

[6]  K. Chin,et al.  Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials , 2012, International journal of clinical practice.

[7]  W. Haefeli,et al.  Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. , 2014, British journal of clinical pharmacology.

[8]  T. Fleming,et al.  New trial designs and potential therapies for pulmonary artery hypertension. , 2013, Journal of the American College of Cardiology.

[9]  J. Loscalzo,et al.  Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). , 2013, The American journal of cardiology.

[10]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[11]  W. Haefeli,et al.  Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1 , 2013, European Journal of Clinical Pharmacology.

[12]  M. Bruzzone,et al.  Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. , 2013, Rheumatology.

[13]  Artemis-Ipf Investigators.  Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial , 2013 .

[14]  W. Haefeli,et al.  Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. , 2013, European journal of pharmacology.

[15]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[16]  M. Allard,et al.  Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension , 2012, Journal of clinical pharmacology.

[17]  D. Kohan,et al.  Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. , 2012, The American journal of cardiology.

[18]  D. Badesch,et al.  152 Post-Marketing Hepatic Safety Profile of Ambrisentan in Patients with Pulmonary Arterial Hypertension – 4 Year Update , 2012 .

[19]  D. Badesch,et al.  ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. , 2009, Cardiovascular therapeutics.

[20]  M. Allard,et al.  Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension: 3-Year Outcome , 2011 .

[21]  R. Ewert,et al.  Ambrisentan Improves Exercise Capacity and Symptoms in Patients with Portopulmonary Hypertension Ambrisentan verbessert die Belastbarkeit und Symptomatik bei Patienten mit portopulmonaler Hypertonie , 2011 .

[22]  R. Oudiz,et al.  Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. , 2011, The American journal of cardiology.

[23]  P. Staehr,et al.  PAH Therapy In HIV: Lack Of Drug-Drug Interaction Between Ambrisentan And Ritonavir , 2011, ATS 2011.

[24]  E. Rosenzweig,et al.  Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. , 2011, The American journal of cardiology.

[25]  Duncan Richards,et al.  Effects of Multiple Doses of Ambrisentan on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Volunteers , 2011, Journal of clinical pharmacology.

[26]  Z. Safdar.  Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension , 2010, Clinical drug investigation.

[27]  R. Boinpally,et al.  Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine , 2010, Clinical pharmacology and therapeutics.

[28]  R. Boinpally,et al.  Steady State Tacrolimus Has No Effect On The Steady State Pharmacokinetics Of Ambrisentan In Healthy Subjects , 2010, ATS 2010.

[29]  R. Boinpally,et al.  Absence Of A Clinically Relevant Pharmacokinetic Interaction Between Ambrisentan And Mycophenolate Mofetil , 2010, ATS 2010.

[30]  S. Matulevicius,et al.  Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. , 2010, Journal of cardiac failure.

[31]  R. Boinpally,et al.  Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects , 2010, Clinical drug investigation.

[32]  R. Boinpally,et al.  No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. , 2009, Journal of pharmaceutical sciences.

[33]  H. Ghofrani,et al.  Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[34]  W. Seeger,et al.  Drug Interactions in Pulmonary Arterial Hypertension and Their Implications , 2009 .

[35]  D. Richards,et al.  Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan , 2009, Journal of clinical pharmacology.

[36]  J. Venitz,et al.  The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. , 2009, British journal of clinical pharmacology.

[37]  D. Despain,et al.  Omeprazole Has No Clinically Relevant Effect on the Pharmacokinetics of Ambrisentan. , 2009, ATS 2009.

[38]  T. Pulido.  Long-Term Ambrisentan Therapy for Pulmonary Arterial Hypertension: Comparison by Etiology. , 2009, ATS 2009.

[39]  D. Badesch,et al.  Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. , 2006, Chest.

[40]  J. Venitz,et al.  Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers , 2008, Journal of clinical pharmacology.

[41]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[42]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[43]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.